Endonovo TherapeuticsENDV
13F holders, Q4 2025 (December 31)1holders
1new positions
0sold out
$0.00avg. 13F price*
At the end of Q4 2025, 1 institutions reported holding Endonovo Therapeutics Inc. (ENDV) in their 13F filings, unchanged from Q2 2025. 1 opened new positions and 0 sold out. The largest holder was Family CFO Inc ($0).
- Company
- Endonovo Therapeutics Inc.
- CUSIP
- 29272H300
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q2 2025 → Q4 2025: 60 shares bought, net +60 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| Family CFO Inc | 0.00% | New | 60 | $0 |
"% of holder's portfolio" is ENDV's weight in each manager's 13F, not the share of Endonovo Therapeutics Inc. the manager owns.